Anavex Life Sciences Corp (AVXL)

[Doc328]

When Doc compares 2-73 to other drugs, he does not adjust for this. That surprises me in a neurologist who does clinical trials....When Doc compares 2-73 to other drugs, he does not adjust for this. That surprises me in a neurologist who does clinical trials.

I'm not sure where this straw man argument comes from. I have never once said that a medication has to be a panacea or that it needs to be effective for the entire population. Anavex must design a study to answer to determine if there is efficacy with any chosen population against either placebo or SOC using an endpoint that the FDA finds relevant.